A novel antibody enabling the detection and qualification of the RTA protein, a key factor in the detection of early Epstein Barr Virus.

Introduction

The R Transactivator (RTA) is one of the two main transactivators originating from the Epstein Barr Virus (EBV). It acts in synergy with the Zebra protein in the switch-latency productive cycle.  The transactivator demonstrates significant potential as a marker for the early detection of EBV infection. This technology is available to license to organisations working in the field of monoclonal antibody distribution.

Features/Benefits

• Monoclonal Antibody
  • Highly targeted
• Validated for use in immunofluorescence/western blotting/Flow cytometry

  • Facilitates use in a research environment
• UVHCI (Unit of Virus Host Cell Interactions), laboratory renowned at a European level
  • Specialists in the understanding of EBV biology

Applications

• Detection of early Epstein Barr Virus infection
• The technology has significant potential within a research environment

Scientific data

References :

Imbert-Marcille et al. Clin. Diagn. Lab Immunol. 7 : 206-211.2000
Feederle R. et al. EMBO J. 19 : 3080-3089.2000

This technology is available to license to organisations working in the field of monoclonal antibody distribution.